Brief: Sarepta Therapeutics Announces Refinancing Of Approximately $291 Million Of 1.25% Convertible Senior Notes Due 2027
11/12/2025 12:46
Dec 11 (Reuters) - Sarepta Therapeutics Inc SRPT.O: SAREPTA THERAPEUTICS ANNOUNCES REFINANCING OF APPROXIMATELY $291 MILLION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2027 SAREPTA THERAPEUTICS INC - TO EXCHANGE $291.4 MILLION EXISTING NOTES FOR NEW NOTES DUE 2030 Source text: ID:nBw2TvRKma Further company coverage: SRPT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sarepta Therapeutics
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Sarepta, Dyne fall after Novartis muscle disorder trial failure